טוען...
Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors
The dual protein kinase-transcription factor, ERK5, is an emerging drug target in cancer and inflammation, and small-molecule ERK5 kinase inhibitors have been developed. However, selective ERK5 kinase inhibitors fail to recapitulate ERK5 genetic ablation phenotypes, suggesting kinase-independent fun...
שמור ב:
| הוצא לאור ב: | Nat Commun |
|---|---|
| Main Authors: | , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Nature Publishing Group UK
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7069993/ https://ncbi.nlm.nih.gov/pubmed/32170057 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-020-15031-3 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|